COVID-19 Pandemic Anniversary + Cancer Biotech Acquisitions

2021-03-24

This podcast was recorded on March 15, 2021In Episode 3 of the Xtalks Life Science Podcast, the team reflects on the 1-year anniversary of the start of the COVID-19 pandemic. Ayesha explains how far we’ve come since March 2020 in terms of vaccine development, but discusses the inequities in distribution of the COVID-19 vaccines despite the establishment of the WHO’s COVAX Facility.Ayesha also discusses the four largest cancer biotech acquisitions of 2021 so far, including deals made by Agilent, Takeda and Amgen. The...

This podcast was recorded on March 15, 2021

In Episode 3 of the Xtalks Life Science Podcast, the team reflects on the 1-year anniversary of the start of the COVID-19 pandemic. Ayesha explains how far we’ve come since March 2020 in terms of vaccine development, but discusses the inequities in distribution of the COVID-19 vaccines despite the establishment of the WHO’s COVAX Facility.

Ayesha also discusses the four largest cancer biotech acquisitions of 2021 so far, including deals made by Agilent, Takeda and Amgen. The team discusses the potential benefits of these acquisitions and shares results of a study that found that innovation can sometimes be stalled when smaller biotech firms are absorbed by big pharmas.

Read the full articles here:

Reflections on the 1-Year Anniversary of the COVID-19 Pandemic

The 4 Biggest Cancer Biotech Acquisitions of 2021 So Far

For more life science and medical device content, visit the Xtalks Vitals homepage.

Twitter: @Xtalks, @XtalksMedDevice
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Comments (3)